Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) on September 25, 2023. The report addresses a corporate governance event under Item 8.01 (Other Events).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a board appointment and does not contain financial performance data.
Material Changes
The Board of Directors appointed Carol Webb to the Audit Committee effective September 25, 2023. This appointment fills the vacancy created by the death of Howard Safir on September 11, 2023. Following this appointment, the Audit Committee consists of three independent members, satisfying Nasdaq Capital Market Listing Rule 5605(c)(2).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Carol Webb has been appointed to the Audit Committee to replace the late Howard Safir.
- The Audit Committee now meets the Nasdaq requirement of having three independent members.
- The filing contains no financial results or operational updates for the period.